Bioequivalence Study Objectives and Endpoints ARGX-113-2312 (NCT05817435) was a Phase 1, open-label, randomized, 2-period crossover bioequivalence study in healthy participants. The objective of this study was to establish the bioequivalence between efgartigimod PH20 SC administered via PFS and V + S following a single health care provider-administered injection.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with De
Contact De, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack